Learn More About PRIMA

PRIMA is approved for commercial use in the European Union. In all other regions, PRIMA is an investigational technology being studied for vision restoration in dry age-related macular degeneration and other forms of retinal atrophy, and is not available for commercial distribution. If you or a family member have one of these conditions, we encourage you to join our patient registry to stay informed about clinical research and future availability.

Sign up to learn more

PRIMA Centers of Excellence

The PRIMA procedure will be exclusively available at these certified centers of excellence.

Who is eligible for PRIMA?

An ophthalmologist using a slit lamp to inspect a patient while a dramatic burst of warm light shines from his lamp on the left side of the image.

  • Your central photoreceptors are damaged but the rest of your eye is healthy

    Current eligibility requirements exclude patients with conditions affecting other parts of the eye, including glaucoma, cataract, wet macular degeneration, corneal disease, optic neuropathy, vein or artery occlusion, or retinal detachment.

  • You have low vision in both eyes

  • The area of atrophy in the eye is large enough to accommodate the implant

Indication status
Age-related macular degenerationApproved in the European Union; Investigational in all other jurisdictions
Stargardt diseaseInvestigational
Retinitis pigmentosaInvestigational

Contraindications

The PRIMA procedure requires specialized vitreoretinal surgical techniques and post-operative rehabilitation. It is exclusively available at certified centers of excellence